DAT antagonists(Dopamine transporter antagonists), NET inhibitors(Norepinephrine transporter inhibitors), SERT inhibitors(Serotonin transporter inhibitors)

Therapeutic Areas

Nervous System DiseasesCongenital DisordersEndocrinology and Metabolic Disease+ [1]

Active Indication-

Inactive Indication

Alzheimer DiseaseDementia due to Alzheimer's disease (disorder)Diabetes Mellitus, Type 2+ [3]

Originator Organization

NTG Nordic Transport Group A/S

Active Organization-

Inactive Organization

Boehringer Ingelheim GmbH

National Institute of Neurological Disorders & Stroke

Saniona AB

+ [1]

License Organization

Saniona AB

Boehringer Ingelheim GmbH

NeuroSearch A/S

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC17H23Cl2NO

InChIKeyVCVWXKKWDOJNIT-ZOMKSWQUSA-N

CAS Registry195875-84-4

Clinical Trials associated with Tesofensine

EUCTR2021-000146-18-SE

/ Not yet recruitingPhase 2

A Phase 2b, Double-blind, Randomized, Placebo-controlled, Dose finding, Multi-center, 36-week Safety and Efficacy Study with Open-label Extension Period of Tesomet in Subjects with Hypothalamic Obesity

Start Date04 Jan 2022

Sponsor / Collaborator-

EUCTR2018-003672-12-DK

/ CompletedPhase 2

A 24-week phase 2, double-blind, randomized, placebo-controlled, single-centre safety and efficacy study to evaluate overall safety and tolerability of co-administration of tesofensine and metoprolol in subjects with hypothalamic injury-induced obesity (HIO), and with a 24-week open-label extension, in total 48 weeks

Start Date16 Jan 2019

Sponsor / Collaborator-

JPRN-UMIN000054277

/ CompletedPhase 3IIT

Clinical study to evaluate the efficacy and safety of Tesofensine on body weight loss and body composition of Mexican patients with obesity. Double-blind, randomized, placebo-controlled, multicenter clinical trial. - TESObesity

Start Date08 Aug 2017

Sponsor / Collaborator

Instituto Politecnico Nacional

100 Clinical Results associated with Tesofensine

100 Translational Medicine associated with Tesofensine

100 Patents (Medical) associated with Tesofensine

Literatures (Medical) associated with Tesofensine

01 Jun 2022·EUROPEAN JOURNAL OF ENDOCRINOLOGYQ1 · MEDICINE

Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity

Q1 · MEDICINE

Article

Author: Tfelt-Hansen, Jacob ; Byberg, Sarah ; Aharaz, Abdellatif ; Magkos, Faidon ; Klose, Marianne ; Madsbad, Sten ; Edsberg, Berit ; Feldt-Rasmussen, Ulla ; Krogsgaard, Kim ; Astrup, Arne Vernon ; Huynh, Kim ; Drejer, Jørgen

Context:

Hypothalamic injury often leads to rapid, intractable weight gain causing hypothalamic obesity, which is associated with increased risk of cardiovascular and metabolic morbidity and mortality. There are no approved or effective pharmacological treatments for hypothalamic obesity, and conventional lifestyle management remains ineffective.

Objective:

To investigate the safety and efficacy of Tesomet (0.5 mg tesofensine/50 mg metoprolol) in adults with hypothalamic obesity.

Methods:

Twenty-one adults with hypothalamic obesity (16 females) were randomized to Tesomet (0.5 mg/50 mg) or placebo for 24 weeks. Patients also received diet/lifestyle counselling. The primary endpoint was safety; secondary endpoints included measures of body weight, appetite scores, quality of life, and metabolic profile.

Results:

Eighteen patients completed 24 weeks. Consent withdrawal, eligibility, and serious adverse events (SAE) unrelated to treatment resulted in dropouts. One patient experienced a Tesomet-related SAE of exacerbated pre-existing anxiety leading to treatment discontinuation. Tesomet-related adverse events were otherwise mostly mild and included sleep disturbances (Tesomet 50%, placebo 13%), dry mouth (Tesomet 43%, placebo 0%), and headache (Tesomet 36%, placebo 0%). No significant differences in heart rate or blood pressure were observed between groups. Compared to placebo, Tesomet resulted in additional mean (95% CI) weight change of −6.3% ((−11.3; −1.3); P = 0.017), increased the number of patients achieving ≥5% weight loss (Tesomet 8/13, placebo 1/8; P = 0.046), and tended to augment the reduction in waist circumference by 5.7 cm ((−0.1; 11.5); P = 0.054).

Conclusion:

Tesomet was welltolerated, did not affect heart rate or blood pressure, and resulted in significant reductions in body weight compared to placebo in adults with hypothalamic obesity.

01 Nov 2021·European journal of internal medicineQ3 · MEDICINE

Future directions in obesity pharmacotherapy

Q3 · MEDICINE

Review

Author: Finer, Nick

There is a growing unmet need for more effective treatment of obesity and its complications. While current anti-obesity medications are effective and offer real clinical benefits over diet and lifestyle interventions, they cannot meet the levels of efficacy and reduction of hard endpoint outcomes seen with bariatric surgery. As knowledge on the control of body weight unravels, the complexity of this physiology opens the opportunity to new druggable targets. Currently, gut peptide analogues such as semaglutide, a glucagon like peptide-1 (GLP-1) receptor agonist, and the dual agonist GLP-1 and gastric inhibitory polypeptide (GIP) tirzepatide are the furthest advanced in clinical development and seem likely to meet current regulatory requirements within the next year or so. However, current regulatory requirements are out of step with the efficacy of new compounds and concepts relating to obesity and its complications. Many other drugs in early development will target different pathways of energy balance, raising the possibility of drug combinations to maximise efficacy as for other chronic disease such as hypertension and diabetes. This will allow more complex and personalised guidelines to evolve.

02 Jun 2021·ACS chemical neuroscienceQ3 · MEDICINE

Understanding the Polypharmacological Profiles of Triple Reuptake Inhibitors by Molecular Simulation

Q3 · MEDICINE

Article

Author: Yao, Xiaojun ; Xue, Weiwei ; Tu, Gao ; Fu, Tingting ; Yang, Jingyi ; Zhang, Zhao ; Zhu, Feng ; Yang, Fengyuan

The triple reuptake inhibitors (TRIs) class is a class of effective inhibitors of human monoamine transporters (hMATs), which includes dopamine, norepinephrine, and serotonin transporters (hDATs, hNETs, and hSERTs). Due to the high degree of structural homology of the binding sites of those transporters, it is a great challenge to design potent TRIs with fine-tuned binding profiles. The molecular determinants responsible for the binding selectivity of TRIs to hDATs, hNETs, and hSERTs remain elusive. In this study, the solved X-ray crystallographic structure of hSERT in complex with escitalopram was used as a basis for modeling nine complexes of three representative TRIs (SEP225289, NS2359, and EB1020) bound to their corresponding targets. Molecular dynamics (MD) and effective post-trajectory analysis were performed to estimate the drug binding free energies and characterize the selective profiles of each TRI to hMATs. The common binding mode of studied TRIs to hMATs was revealed by hierarchical clustering analysis of the per-residue energy. Furthermore, the combined protein-ligand interaction fingerprint and residue energy contribution analysis indicated that several conserved and nonconserved "Warm Spots" such as S149, V328, and M427 in hDAT, F317, F323, and V325 in hNET and F335, F341, and V343 in hSERT were responsible for the TRI-binding selectivity. These findings provided important information for rational design of a single drug with better polypharmacological profiles through modulating multiple targets.

News (Medical) associated with Tesofensine

26 May 2026

·saniona.com

Saniona publishes its interim report for the first quarter of 2026

Comments from the CEO“In the first quarter of 2026, we continued disciplined execution of our partnership-driven strategy. With three proprietary programs supported by GLP toxicology material, we are preparing to enter the clinic. Our partnered assets offer near-term milestone potential, while our internal pipeline advances toward key value inflection points. Engagement with international investment and pharmaceutical communities is strengthening. We remain focused on operating partly self-financed through partnerships, while maintaining strategic flexibility for future growth. Saniona is positioned for the next phase of clinical and shareholder value creation.”Investor callSaniona will host a Q1 investor call on 26 May 2026, at 11.00 CEST.At the call Management will be presenting results and a company update. At the end of the presentation there will be a Q&A session, where participants can ask online questions.Access to the event can be obtained through the following link:https://www.redeye.se/events/1143627/live-q-saniona-5REPLAY accessWebcast replay will be available at www.saniona.com and at www.redeye.se About SanionaSaniona is a clinical-stage biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders. The company’s internal pipeline includes SAN2668 for paediatric epilepsy syndromes, SAN2219 for epilepsy, and SAN2465 for major depressive disorder. Saniona has established strategic collaborations with leading pharmaceutical companies, including Jazz Pharmaceuticals, which holds global rights to SAN2355 for epilepsy, Acadia Pharmaceuticals, which holds worldwide rights to ACP-711 for essential tremor, and with Medix, which holds rights to tesofensine for obesity in Mexico, where a market authorization application is currently under review, and Argentina. Saniona’s ion channel discovery platform is further validated through research collaborations with Boehringer Ingelheim, AstronauTx, and Cephagenix. Headquartered in Copenhagen, Saniona is listed on the Nasdaq Stockholm Main Market.For more information, visit www.saniona.com.

20 May 2026

·saniona.com

Invitation to Saniona Q1 investor call on 26 May 2026

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, will host a Q1 investor call on 26 May 2026, at 11.00 CEST At the call Management will be presenting results and a company update. At the end of the presentation there will be a Q&A session, where participants can ask online questions.Access to the event can be obtained through the following link: https://www.redeye.se/events/1143627/live-q-saniona-5 REPLAY accessWebcast replay will be available at www.saniona.com and at www.redeye.se About SanionaSaniona is a clinical-stage biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders. The company’s internal pipeline includes SAN2668 for paediatric epilepsy syndromes, SAN2219 for epilepsy, and SAN2465 for major depressive disorder. Saniona has established strategic collaborations with leading pharmaceutical companies, including Jazz Pharmaceuticals, which holds global rights to SAN2355 for epilepsy, Acadia Pharmaceuticals, which holds worldwide rights to ACP-711 for essential tremor, and with Medix, which holds rights to tesofensine for obesity in Mexico, where a market authorization application is currently under review, and Argentina. Saniona’s ion channel discovery platform is further validated through research collaborations with Boehringer Ingelheim, AstronauTx, and Cephagenix. Headquartered in Copenhagen, Saniona is listed on the Nasdaq Stockholm Main Market.For more information, visit www.saniona.com.

30 Apr 2026

·saniona.com

Saniona publishes its Annual Report for 2025

Saniona (OMX: SANION) a clinical-stage biopharmaceutical company, today announced that the English version of the Annual Report 2025 is now available on the company’s website, www.saniona.com. About SanionaSaniona is a clinical-stage biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders. The company’s internal pipeline includes SAN2668 for paediatric epilepsy syndromes, SAN2219 for epilepsy, and SAN2465 for major depressive disorder. Saniona has established strategic collaborations with leading pharmaceutical companies, including Jazz Pharmaceuticals, which holds global rights to SAN2355 for epilepsy, Acadia Pharmaceuticals, which holds worldwide rights to ACP-711 for essential tremor, and with Medix, which holds rights to tesofensine for obesity in Mexico, where a market authorization application is currently under review, and Argentina. Saniona’s ion channel discovery platform is further validated through research collaborations with Boehringer Ingelheim, AstronauTx, and Cephagenix. Headquartered in Copenhagen, Saniona is listed on the Nasdaq Stockholm Main Market.For more information, visit www.saniona.com.

100 Deals associated with Tesofensine

External Link

KEGG	Wiki	ATC	Drug Bank
-	Tesofensine	-	DB06156

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Prader-Willi Syndrome	Phase 2	Czechia	Saniona AB	30 Mar 2017
Diabetes Mellitus, Type 2	Phase 2	Germany	Saniona AB	01 Apr 2016
Obesity	Phase 2	Denmark	NTG Nordic Transport Group A/S	01 Sep 2006
Dementia due to Alzheimer's disease (disorder)	Phase 2	United States	Boehringer Ingelheim GmbH	01 Feb 2003
Dementia due to Alzheimer's disease (disorder)	Phase 2	Canada	Boehringer Ingelheim GmbH	01 Feb 2003
Parkinson Disease	Phase 2	United States	National Institute of Neurological Disorders & Stroke	01 Aug 2000
Alzheimer Disease	Phase 2	United States	Boehringer Ingelheim GmbH	-
Alzheimer Disease	Phase 2	Canada	Boehringer Ingelheim GmbH	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis